Glycomine Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $115M

  • Investors
  • 22

Glycomine General Information

Description

Developer of orphan drugs designed to treat rare disorders of metabolism and protein misfolding. The company's drugs combine replacement therapies such as substrates, enzymes, and proteins with intracellular delivery vehicles consisting of bio-nano materials and ligands that target the molecules to the cell interior of clinically relevant organs, enabling physicians to efficiently treat their patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • MBC BioLabs
  • 733 Industrial Road
  • San Carlos, CA 94070
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • MBC BioLabs
  • 733 Industrial Road
  • San Carlos, CA 94070
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Glycomine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 14-May-2026 $115M Completed Clinical Trials - Phase 2
4. Later Stage VC (Series B) 11-Jun-2021 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 16-Nov-2016 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 01-Jan-2016 $630K $630K Completed Clinical Trials - Phase 1
1. Accelerator/Incubator 11-Mar-2015 Completed Pre-Clinical Trials
To view Glycomine’s complete valuation and funding history, request access »

Glycomine Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B-2
Series B-1 61,114,556 $0.000100 $0.67 $0.67 1x $0.67 16.67%
Series A 1,337,056 $0.000100 $3.8 $3.8 1x $3.8 0.36%
To view Glycomine’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Glycomine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of orphan drugs designed to treat rare disorders of metabolism and protein misfolding. The company's drugs com
Drug Discovery
San Carlos, CA
20 As of 2022

New York, NY
 

White Bear Lake, MN
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Glycomine Competitors (52)

One of Glycomine’s 52 competitors is Cognition Therapeutics, a Formerly VC-backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cognition Therapeutics Formerly VC-backed New York, NY
MnPharm Venture Capital-Backed White Bear Lake, MN
Regenerx Formerly VC-backed Rockville, MD
Carisma Therapeutics Formerly VC-backed Philadelphia, PA
MiNA Therapeutics Venture Capital-Backed London, United Kingdom
You’re viewing 5 of 52 competitors. Get the full list »

Glycomine Patents

Glycomine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026226709-A1 Mrna therapy for pmm2 Pending 24-Apr-2025
AU-2025230053-A1 Liposomal formulations, and methods of using and preparing thereof Pending 29-Feb-2024
WO-2025184398-A1 Liposomal formulations, and methods of using and preparing thereof Pending 29-Feb-2024
AU-2025228129-A1 Methods of treating congenital disorders of glycosylation (cdg) and ataxia in subjects suffering from cdg Pending 29-Feb-2024
WO-2025184395-A1 Methods of treating congenital disorders of glycosylation (cdg) and ataxia in subjects suffering from cdg Pending 29-Feb-2024 A61P25/00
To view Glycomine’s complete patent history, request access »

Glycomine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glycomine Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aberdeen Investments (Scotland) Asset Manager Minority
Advent Life Sciences Venture Capital Minority
CTI Life Sciences Fund Venture Capital Minority
Tekla World Healthcare Fund Asset Manager Minority
Abingworth Venture Capital Minority
You’re viewing 5 of 22 investors. Get the full list »

Glycomine FAQs

  • When was Glycomine founded?

    Glycomine was founded in 2015.

  • Where is Glycomine headquartered?

    Glycomine is headquartered in San Carlos, CA.

  • What is the size of Glycomine?

    Glycomine has 20 total employees.

  • What industry is Glycomine in?

    Glycomine’s primary industry is Drug Discovery.

  • Is Glycomine a private or public company?

    Glycomine is a Private company.

  • What is the current valuation of Glycomine?

    The current valuation of Glycomine is .

  • What is Glycomine’s current revenue?

    The current revenue for Glycomine is .

  • How much funding has Glycomine raised over time?

    Glycomine has raised $196M.

  • Who are Glycomine’s investors?

    Aberdeen Investments (Scotland), Advent Life Sciences, CTI Life Sciences Fund, Tekla World Healthcare Fund, and Abingworth are 5 of 22 investors who have invested in Glycomine.

  • Who are Glycomine’s competitors?

    Cognition Therapeutics, MnPharm, Regenerx, Carisma Therapeutics, and MiNA Therapeutics are some of the 52 competitors of Glycomine.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process